Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-09

Clinical Trial Update: A Study of LY3023414 and Necitumumab in Squamous Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of LY3023414 and necitumumab in metastatic non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LY3023414 (samotolisib)
  • Necitumumab (necitumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2020-12-09